Brain Abscess

Hematogenous Seeding and Establishment

• Bacteria cross the blood-brain barrier through areas of disrupted vasculature, typically at gray-white matter junctions where vessel caliber decreases
• Initial infection triggers local inflammatory response with recruitment of polymorphonuclear leukocytes, creating a zone of cerebritis before abscess capsule formation
• The blood-brain barrier dysfunction allows antibiotics better penetration during early cerebritis (days 1-3) than during mature abscess formation

Abscess Maturation and Capsule Formation

• Over 4-14 days, the lesion progresses through stages: early cerebritis (days 1-3), late cerebritis with central necrosis (days 4-9), and early-to-late encapsulation (days 10-14 onward)
• Fibroblasts from surrounding vasculature form a collagenous capsule that becomes increasingly impermeable to antibiotics
• The mature abscess contains a central core of pus (necrotic debris, dead organisms, and leukocytes) surrounded by granulation tissue with inflammatory cells, then outer glial/fibroblastic capsule
• Capsule thickness and impermeability directly correlate with abscess age; mature abscesses demonstrate decreased antibiotic penetration by 5-50-fold compared to early cerebritis

Pathogenic Bacterial Mechanisms

• Bacteria produce virulence factors (proteases, lipopolysaccharides) that promote tissue invasion and impair local immune clearance
• Microorganisms in the abscess core are often in stationary phase with reduced metabolic activity, rendering them less susceptible to many bactericidal antibiotics
• Acidic, hypoxic microenvironment within abscess promotes selective bacterial survival while inhibiting phagocytic function
• Biofilm formation within mature abscesses provides additional protection from antimicrobial agents and innate immunity

Host Immune Response and Neural Complications

• Surrounding cerebral edema results from increased vascular permeability and accumulation of inflammatory mediators (cytokines, prostaglandins)
• Local mass effect causes increased intracranial pressure with potential herniation; perilesional edema often exceeds the abscess size itself
• Seizures result from irritation of adjacent cortex by inflammatory mediators and abscess-induced architectural distortion

Predisposing Conditions Facilitating Hematogenous Seeding

• Cyanotic congenital heart disease (tetralogy of Fallot, transposition of great arteries): bypass of splenic filtration and impaired opsonization; most common cause in pediatric populations
• Bacterial endocarditis: septic emboli with direct bacterial seeding; accounts for 15-20% of brain abscesses
• Pulmonary arteriovenous fistulas: bypass of lung filtration
• Chronic pulmonary disease: bronchiectasis, lung abscess, empyema (accounts for 20-25% of cases)
• Immunocompromised states (HIV/AIDS, chemotherapy, solid organ transplantation): particularly Toxoplasma gondii in CD4 <100 cells/μL
• Intra-abdominal infections: appendicitis, diverticulitis, inflammatory bowel disease (rare but important source)

Direct Extension and Trauma

• Parameningeal foci: otitis media, mastoiditis, sinusitis (particularly frontal and sphenoid sinuses) account for 30-40% of cases
• Penetrating head trauma: including neurosurgical procedures, epidural/subdural hematoma evacuation
• Dental procedures and poor dentition: anaerobic oral flora (Peptostreptococcus, Prevotella, Fusobacterium)

Common Causative Organisms

• Streptococci (viridans group, Streptococcus bovis, Streptococcus anginosus group—the most common overall): 40-60% of cases
• Staphylococcus aureus (including MRSA): 20-30%, particularly in trauma and endocarditis
• Gram-negative bacilli (E. coli, Klebsiella, Enterobacter, Citrobacter): particularly in immunocompromised hosts and intra-abdominal sources
• Anaerobic bacteria (Peptostreptococcus, Prevotella, Fusobacterium, Clostridium): 50-80% of cases overall, often polymicrobial
• Toxoplasma gondii: 6-10% in patients with AIDS and CD4 <100 cells/μL (most common CNS infection in AIDS before HAART)
• Nocardia: in severely immunocompromised patients
• Fungi (Cryptococcus, Candida, Aspergillus, Coccidioides): primarily in severely immunocompromised hosts
• Mycobacterium tuberculosis: tuberculoma; important in endemic regions

Primary Neurological Symptoms

• Headache: present in 50-80% (often progressive, may be localized or generalized; typically worse in morning due to increased ICP during sleep)
• Focal neurological deficits: 50-80% (hemiparesis most common, followed by aphasia, visual field defects, ataxia depending on abscess location)
• Seizures: 25-50% (may be initial presentation; can be focal or generalized; more common with superficial/cortical abscesses)
• Fever: only 50-60% (notably absent in 40-50% despite active infection—critical diagnostic trap)
• Altered mental status/confusion: 25-40% (from increased ICP or direct effect on consciousness centers)

Physical Examination Findings

• Meningismus (neck stiffness, Kernig/Brudzinski signs): less common than in meningitis; when present suggests ventriculitis or rupture into ventricular system
• Focal neurological signs: correspond to abscess location (e.g., motor deficits with motor strip involvement, visual field cuts with temporal lobe)
• Papilledema and vital sign abnormalities (bradycardia, hypertension): signs of elevated intracranial pressure
• Organomegaly and heart murmurs: findings suggesting underlying endocarditis or chronic pulmonary disease

Atypical Presentations

• Immunocompromised patients may present with minimal fever and indolent courses
• Multiple abscesses (10-25% of cases, more common in immunocompromised hosts) may present with disseminated neurological symptoms
• Aspiration risk patients: subtle presentation with lethargy and cognitive changes

Neuroimaging: Gold Standard

• Contrast-enhanced MRI: superior modality
• T1-weighted with gadolinium: peripheral ring enhancement with central low signal (nonenhancing purulent core)
• T2-weighted/FLAIR: markedly hyperintense core with surrounding vasogenic edema (hyperintense)
• Diffusion-weighted imaging (DWI): restricted diffusion within abscess core (hyperintense on DWI, hypointense on ADC map)—helps differentiate abscess from cystic neoplasms or hematomas
• Multiple abscesses visible in 10-25% of cases
• Timing: repeat imaging at 2-4 weeks to assess interval evolution and guide therapy duration

• Non-contrast CT: initial screening modality when MRI unavailable
• Hypodense core with hyperdense ring enhancement after contrast
• Perilesional edema visible as hypodense halo
• Less sensitive than MRI for small abscesses (<1 cm) and posterior fossa lesions

Lumbar Puncture

• Generally contraindicated in suspected brain abscess due to risk of herniation from mass effect and raised ICP
• CSF analysis (if obtained, typically shows):
• Pleocytosis (10-1000 WBC/μL, though may be <50 in 25% of cases—another diagnostic trap)
• Glucose: normal or mildly elevated (unlike bacterial meningitis)
• Protein: mildly elevated (50-200 mg/dL)
• Cultures: positive in <10% of cases
• LP only appropriate after neuroimaging excludes mass effect and only if high suspicion for meningitis coexists

Blood and Culture Data

• Blood cultures: positive in 50-70% with hematogenous source (endocarditis, pulmonary), but only 10-20% overall
• Peripheral WBC: elevated in 50-70% but may be normal
• ESR/CRP: nonspecific elevations in 50%

Microbiological Diagnosis

• Stereotactic needle aspiration or biopsy: gold standard for organism identification
• Gram stain and culture of aspirate
• Anaerobic cultures essential (require special transport/handling)
• Fungal, mycobacterial cultures if immunocompromised
• Sensitivity 80-100% depending on technique
• Reserved for: diagnostic uncertainty, failure to improve on empiric therapy, immunocompromised hosts with atypical features

Diagnostic Criteria

• Combination of clinical suspicion, characteristic neuroimaging (ring-enhancing lesion with restricted diffusion), and microbiological confirmation
• Modified Glioma Criteria Score or Luxembourg classification can help differentiate abscess from other ring-enhancing lesions

Medical Management: First-Line Antimicrobial Therapy

• Third-generation cephalosporin (ceftriaxone 2g IV q12h) PLUS vancomycin (15-20 mg/kg IV q8-12h) PLUS metronidazole (500 mg IV q6-8h)
• Cephalosporin covers viridans streptococci and gram-negative bacilli with good CNS penetration
• Vancomycin covers penicillin-resistant streptococci and MRSA
• Metronidazole essential for anaerobic coverage (part of >50% of abscesses)
• Continue empiric therapy for 10-14 days pending culture results

• For immunocompromised patients (CD4 <100): add TMP-SMX (for Toxoplasma coverage) or empirically treat as toxoplasmosis with sulfadiazine + pyrimethamine until toxoplasma serology/imaging/PCR clarified

• For recent neurosurgery/trauma or suspected MRSA (colonization, healthcare exposure): ensure vancomycin coverage

• Streptococcus species (penicillin-susceptible): penicillin G 4 million units IV q4h or ceftriaxone (continue above regimen)
• MRSA/Penicillin-resistant Streptococcus pneumoniae: vancomycin + ceftriaxone/cefotaxime
• Gram-negative bacilli (E. coli, Klebsiella): ceftriaxone or cefotaxime; add aminoglycoside if inadequate response
• Anaerobes: metronidazole or clindamycin (600 mg IV q6h); chloramphenicol alternative if β-lactam allergy
• Toxoplasma (in AIDS): sulfadiazine 1.5g IV q6h + pyrimethamine 50-100mg daily + leucovorin (folinic acid) 10-20mg daily for toxicity prevention
• Nocardia: TMP-SMX (high-dose: 15 mg/kg/day TMP component) ± amikacin
• Fungal (varies by organism): amphotericin B ± flucytosine for cryptococcal/candidal; voriconazole for aspergillal

Duration of Therapy

• Standard course: 6-8 weeks total IV antibiotics from initiation (not from culture date)
• First 2 weeks: full doses as above
• Weeks 2-8: may transition to oral agents if significant clinical/radiographic improvement (e.g., vancomycin to linezolid, cephalosporin to fluoroquinolone + rifampin)
• Shorter durations (4 weeks) reported for small (<2 cm), well-encapsulated abscesses with good clinical response
• Longer durations (10-12 weeks) for immunocompromised hosts or multiple abscesses

Adjunctive Anti-inflammatory Therapy

• Dexamethasone: 10 mg IV q6h for 3-5 days, then taper
• Reduces vasogenic edema and mass effect
• Use particularly for elevated ICP or threatened herniation
• Timing: most benefit when given with or shortly after antibiotics; may be withheld initially to avoid decreased antibiotic penetration (controversial)
• Monitor for immunosuppressive effects and hyperglycemia

Surgical Intervention

• Emergent: impending herniation, significant mass effect with midline shift, intraventricular rupture
• Urgent: immunocompromised hosts (especially AIDS)
• Elective: failure to improve clinically/radiographically after 3-5 days of appropriate antibiotics, multiple abscesses (particularly if larger ones), large abscesses (>3 cm), posterior fossa location with brainstem compression
• Diagnostic: when organism unidentified and imaging/clinical features atypical

• Stereotactic needle aspiration: minimally invasive, allows culture/sensitivities, therapeutic decompression; most commonly used approach
• Craniotomy with excision: reserved for encapsulated abscess accessible without traversing eloquent cortex; allows complete removal
• Burr hole drainage: for superficial abscesses near surface
• Repeat procedures: 25-50% of patients require repeat aspiration/drainage

• Optimal timing: after 3-5 days of IV antibiotics to allow demarcation of abscess cavity (earlier aspiration may yield seeded pus into ventricular system)
• Exception: emergent cases with herniation or ventriculitis warrant immediate intervention

Management of Seizures

• Prophylactic antiepileptic drugs (phenytoin, levetiracetam) for all patients; particularly important in cortical abscesses
• Seizures occurring on prophylaxis warrant therapeutic drug level verification and addition of second agent
• Continue for minimum 3-6 months, consider lifelong therapy if seizures recur

Supportive Care and Monitoring

• ICU-level monitoring for ICP, hemodynamics, neurological status
• Serial neuroimaging (MRI at 2-4 weeks, then 8-12 weeks) to assess response and guide therapy duration
• Management of increased ICP: head of bed elevation 30°, osmotic therapy (mannitol, hypertonic saline), sedation/analgesia as needed, intracranial pressure monitoring if available
• Anticonvulsants as noted
• Nutritional support

Neurological Complications

• Seizures: occur in 25-50% acutely, persist in 10-20% long-term; manage with antiepileptic drugs and abscess-directed therapy

• Ventriculitis (from abscess rupture into lateral/third/fourth ventricles): catastrophic complication with mortality >50%
• Presents with abrupt worsening of mental status, high fever, stiff neck
• Requires emergent burr hole or external ventricular drain for CSF drainage and antibiotic delivery
• Neuroimaging shows ventricular dilatation, debris/enhancement within ventricles

• Subdural empyema: abscess breakthrough into subdural space
• Presents with rapid neurological deterioration, hemiparesis, seizures
• Requires emergent surgical drainage via craniotomy
• Associated with significantly worsened prognosis

Buzzwords that define the diagnosis

• Ring-enhancing lesion with central restricted diffusion: the single most tested image finding. Pus is viscous and cell-dense, so DWI is bright and ADC is dark. Necrotic glioblastoma and metastases show facilitated diffusion (dark DWI, bright ADC) — the classic distractor pair.
• Contrast-enhanced MRI is the best next step, not lumbar puncture: LP is unlikely to yield the organism and risks herniation, so it rarely changes management in a stem describing a focal mass lesion.
• ***Streptococcus anginosus* (milleri) group**: the organism examiners tie to abscess formation anywhere (brain, liver, lung). Suspect it with sinusitis, dental sepsis, or an oropharyngeal source; anaerobes are frequently co-isolated, which is why metronidazole belongs in the empiric regimen.

The associations most likely to appear in a stem

• Right-to-left shunt — cyanotic congenital heart disease or a pulmonary AV malformation (think hereditary hemorrhagic telangiectasia) — lets bacteria bypass the pulmonary capillary filter. Brain abscess in a young adult with recurrent epistaxis and mucocutaneous telangiectasias should prompt screening for pulmonary AVM.
• Source predicts location: frontal/ethmoid sinusitis → frontal lobe; otitis media or mastoiditis → temporal lobe or cerebellum; hematogenous seeding → multiple lesions in the middle cerebral artery territory.

Discriminating the ring-enhancing lesion in AIDS

• CD4 <100 with multiple lesions favoring basal ganglia: per the CDC/NIH/IDSA Opportunistic Infections guidelines, start empiric pyrimethamine–sulfadiazine–leucovorin for Toxoplasma and repeat imaging at roughly 10–14 days; radiographic and clinical improvement supports the diagnosis.
• Features that raise suspicion for primary CNS lymphoma — a solitary periventricular lesion, negative toxoplasma IgG, positive CSF EBV DNA, or failure to respond to empiric therapy — shift probability but are not diagnostic; they justify proceeding to stereotactic biopsy for confirmation.

Distractors to avoid

• Vancomycin monitoring: dose to a 24-hour AUC/MIC of 400–600 per the 2020 IDSA/ASHP consensus. The older trough-only target of 15–20 mcg/mL is no longer the preferred monitoring strategy for serious MRSA infection per that consensus.
• Steroids are not a reflex: reserve dexamethasone for mass effect or threatened herniation, since it can blunt capsule formation and antibiotic penetration.